Latest Health News

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.

Nex Metals and its Aboriginal partner WTAC have applied for a 100ha lease to build processing infrastructure for the Kookynie Tailings Project, while metallurgical tests show promising gold recovery rates and potential tungsten by-product.

Integral Diagnostics (ASX: IDX) delivered a robust FY26 with 26% revenue growth to $788.6 million, a 677% surge in profit after tax to $22 million, and a 50% hike in its final dividend to 6 cents per share.

Carindale Property Trust (ASX: CDP) reported a robust 50.7% jump in net profit for FY26, boosted by a $25.6 million property revaluation gain, alongside an 8.8% rise in funds from operations and a 5% lift in distributions.

XPON Technologies (ASX: XPN) posted a $1.1 million positive EBITDA in FY26 on 38% revenue growth, shedding Alpha Digital and selling its Google Marketing business to focus on its Wondaris AI platform.

Tyro Payments delivered a robust FY26 with profit before tax up 40%, driven by growth in payments and banking, alongside strategic expansion via the Thriday acquisition and new CEO Nigel Lee’s leadership.

3P Learning reports a statutory net profit of $9.9 million and a 26% rise in underlying EBITDA to $19.5 million for FY26, declaring a 3.52 cent dividend after more than a decade.

Acusensus posted a 45% jump in FY26 revenue to $86.2 million, driven by major contract wins in New Zealand and the US, alongside robust domestic expansions. Despite a widened net loss due to a $16 million litigation settlement, adjusted EBITDA climbed 49%, reflecting operational momentum and strategic investments.

Big River Industries (ASX:BRI) reversed a $14.8 million loss in FY25 to a $4.9 million profit in FY26, driven by margin expansion and the acquisition of Johns Building Supplies. The group targets double-digit EBITDA growth in FY27 amid mixed market conditions.

Austin Engineering's FY26 results reveal a 12.7% revenue drop and a 53.7% EBITDA decline, driven by operational setbacks in the Americas and a loss-making Chile contract. Improved cash flow and safety metrics offer a silver lining as the company embarks on a reset for FY27.

McGrathNicol Restructuring has been appointed voluntary administrators to Australian Pacific Coal and several subsidiaries, signalling a critical phase in the company’s financial and operational review. The Dartbrook Mine sale continues under receivership, with shares remaining suspended.